Latest filing published 24 Apr 2017 for AGIOS PHARMACEUTICALS, INC., €28.5M.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Based on 4 purchases whose 90-day window has closed (published at least 91 days ago), the same population our ranking model reads.
Purchases by company
Since each purchase
- +68.1%Entry US$50.20 · Close at T+365 US$84.38
- -46.1%Entry US$119.62 · Close at T+365 US$64.44
- +122.1%Entry US$43.28 · Close at T+365 US$96.13
- +96.0%Entry US$23.58 · Close at T+365 US$46.22
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Celgene European Investment Co LLC: trading record in brief
Celgene European Investment Co LLC has filed trades across 2 companies (mainly through SEC (Form 4)), most often in Agios Pharmaceuticals, Inc. and Epizyme, Inc. We count 9 filings; the first trade dates from 5 June 2013 and the latest from 24 April 2017.
The open-market record is one-sided, with 6 purchases worth €75.9M and not one sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. So far in 2017, the count stands at 1 purchase and no sales.
In size, the median ticket on the buying side is €9.5M. Looking at 4 purchases old enough to measure, the stock rose over the following 90 days in 50% of cases; the median change was -1.4%. They describe history only and say nothing certain about the share price ahead.
The newest entry dates from 24 April 2017: an open-market purchase of €28.5M, in Agios Pharmaceuticals, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. For comparison, the SEC allows two business days to file a Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Celgene European Investment Co LLC
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 624,575 shares@ US$49.50100.0% of flowCommon StockSEC:0001209191-17-027983:0Canonical exit: 23 Jul 2017 (T+90)
- 228,645 shares@ US$110.75Common StockSEC:0001209191-14-076273:0Canonical exit: 16 Mar 2015 (T+90)
- 294,800 shares@ US$44.00Common StockSEC:0001209191-14-029869:0Canonical exit: 28 Jul 2014 (T+90)
- 340,000 shares@ US$29.25Common StockSEC:0001209191-14-009116:0Canonical exit: 11 May 2014 (T+90)
- 1,887,473 sharesCommon StockSEC:0001209191-13-038260:0
- 2,123,453 sharesCommon StockSEC:0001209191-13-038260:1
- 708,333 shares@ US$18.00Common StockSEC:0001209191-13-038260:2Canonical exit: 27 Oct 2013 (T+90)
- 3,267,974 sharesCommon StockSEC:0001209191-13-030969:0
- 66,666 shares@ US$15.00Common StockSEC:0001209191-13-030969:1Canonical exit: 3 Sept 2013 (T+90)
9 of 9 declarations
